Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced the launch of a chemically-defined, animal-component free media designed to greatly increase the productivity and viability of Selexis SURE CHO-M cell lines. This product, developed in collaboration with Irvine Scientific is designed exclusively for Selexis. The new formulation is called BalanCD CHO SLX A, improves cell viability, increases productivity during pilot and process development, and maintains consistency between runs. These and other benefits should facilitate scale-up in bioreactors.
Irvine Scientific, using its Rational Culture Media Design approach, worked with researchers at Selexis to develop a custom formulation that allows rapid optimization of processes where the SUREtechnology Platform is being evaluated or used.
In combination with our SUREtechnology Platform, BalanCD CHO SLX A is an important new resource to further assist users in speeding drug development while reducing production costs and risks.
BalanCD CHO SLX A represents an important expansion of Irvine Scientific’s portfolio of chemically-defined media. But more importantly provides a more complete solution to customers that need to increase the speed with which they evaluate cell lines, the quality of proteins developed, and optimization of process development. The collaboration with Selexis can provide all these benefits to users with CHO platforms for their protein therapeutics.
